DE69936781T2 - Kvlqt1 - im zusammenhang mit 'long qt syndrom' - Google Patents
Kvlqt1 - im zusammenhang mit 'long qt syndrom' Download PDFInfo
- Publication number
- DE69936781T2 DE69936781T2 DE69936781T DE69936781T DE69936781T2 DE 69936781 T2 DE69936781 T2 DE 69936781T2 DE 69936781 T DE69936781 T DE 69936781T DE 69936781 T DE69936781 T DE 69936781T DE 69936781 T2 DE69936781 T2 DE 69936781T2
- Authority
- DE
- Germany
- Prior art keywords
- kvlqt1
- seq
- gene
- dna
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000004731 long QT syndrome Diseases 0.000 title claims abstract description 156
- 108010011185 KCNQ1 Potassium Channel Proteins 0.000 title claims abstract description 53
- 102000014021 KCNQ1 Potassium Channel Human genes 0.000 title claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 293
- 230000035772 mutation Effects 0.000 claims abstract description 150
- 108020004414 DNA Proteins 0.000 claims abstract description 83
- 238000003556 assay Methods 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 24
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims description 195
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 187
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 159
- 229920001184 polypeptide Polymers 0.000 claims description 146
- 239000000523 sample Substances 0.000 claims description 107
- 150000007523 nucleic acids Chemical class 0.000 claims description 92
- 102000039446 nucleic acids Human genes 0.000 claims description 82
- 108020004707 nucleic acids Proteins 0.000 claims description 82
- 108700028369 Alleles Proteins 0.000 claims description 75
- 101001026226 Homo sapiens Potassium voltage-gated channel subfamily KQT member 1 Proteins 0.000 claims description 66
- 230000000694 effects Effects 0.000 claims description 50
- 230000027455 binding Effects 0.000 claims description 43
- 238000009739 binding Methods 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 43
- 238000012217 deletion Methods 0.000 claims description 38
- 230000037430 deletion Effects 0.000 claims description 38
- 239000013598 vector Substances 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 238000009396 hybridization Methods 0.000 claims description 31
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 230000000295 complement effect Effects 0.000 claims description 27
- 230000003321 amplification Effects 0.000 claims description 26
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 26
- 108020004999 messenger RNA Proteins 0.000 claims description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 23
- 239000000499 gel Substances 0.000 claims description 20
- 238000012163 sequencing technique Methods 0.000 claims description 19
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000002853 nucleic acid probe Substances 0.000 claims description 16
- 238000003780 insertion Methods 0.000 claims description 15
- 230000037431 insertion Effects 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 14
- 238000003745 diagnosis Methods 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 102000053010 human KCNQ1 Human genes 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 238000007901 in situ hybridization Methods 0.000 claims description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 3
- 238000003119 immunoblot Methods 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 238000003287 bathing Methods 0.000 claims 2
- 239000013614 RNA sample Substances 0.000 claims 1
- 238000003365 immunocytochemistry Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 238000012502 risk assessment Methods 0.000 claims 1
- 101000974726 Homo sapiens Potassium voltage-gated channel subfamily E member 1 Proteins 0.000 abstract description 120
- 102100022755 Potassium voltage-gated channel subfamily E member 1 Human genes 0.000 abstract description 115
- 102000004169 proteins and genes Human genes 0.000 abstract description 104
- 102100037444 Potassium voltage-gated channel subfamily KQT member 1 Human genes 0.000 abstract description 45
- 108700024394 Exon Proteins 0.000 abstract description 22
- 238000013461 design Methods 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 97
- 235000018102 proteins Nutrition 0.000 description 96
- 125000003729 nucleotide group Chemical group 0.000 description 70
- 239000002773 nucleotide Substances 0.000 description 69
- 239000002299 complementary DNA Substances 0.000 description 68
- 239000013615 primer Substances 0.000 description 62
- 239000012634 fragment Substances 0.000 description 58
- 108091006146 Channels Proteins 0.000 description 52
- 230000006870 function Effects 0.000 description 51
- 102000040430 polynucleotide Human genes 0.000 description 48
- 108091033319 polynucleotide Proteins 0.000 description 48
- 239000002157 polynucleotide Substances 0.000 description 48
- 210000000287 oocyte Anatomy 0.000 description 46
- 230000000747 cardiac effect Effects 0.000 description 44
- 239000000047 product Substances 0.000 description 40
- 238000012360 testing method Methods 0.000 description 40
- 235000001014 amino acid Nutrition 0.000 description 38
- 230000002159 abnormal effect Effects 0.000 description 37
- 206010003119 arrhythmia Diseases 0.000 description 37
- 210000000349 chromosome Anatomy 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 33
- 108091028043 Nucleic acid sequence Proteins 0.000 description 32
- 238000003752 polymerase chain reaction Methods 0.000 description 32
- 239000000126 substance Substances 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 31
- 241000282414 Homo sapiens Species 0.000 description 29
- 238000012216 screening Methods 0.000 description 28
- 230000006793 arrhythmia Effects 0.000 description 26
- 238000006467 substitution reaction Methods 0.000 description 26
- 238000011282 treatment Methods 0.000 description 26
- 230000004913 activation Effects 0.000 description 25
- 239000003446 ligand Substances 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 108020001213 potassium channel Proteins 0.000 description 24
- 201000010099 disease Diseases 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 22
- 102000004257 Potassium Channel Human genes 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 241000772415 Neovison vison Species 0.000 description 18
- 230000008859 change Effects 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 230000006798 recombination Effects 0.000 description 17
- 238000005215 recombination Methods 0.000 description 17
- 230000002336 repolarization Effects 0.000 description 17
- 108091026890 Coding region Proteins 0.000 description 16
- 108020004705 Codon Proteins 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 15
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 238000012546 transfer Methods 0.000 description 15
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 230000009849 deactivation Effects 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000013507 mapping Methods 0.000 description 13
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 12
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 12
- 230000003111 delayed effect Effects 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 230000002068 genetic effect Effects 0.000 description 12
- 210000002216 heart Anatomy 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 102200133010 rs74315445 Human genes 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 241000269370 Xenopus <genus> Species 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 108010052164 Sodium Channels Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 102000018674 Sodium Channels Human genes 0.000 description 9
- 239000013543 active substance Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 108091092195 Intron Proteins 0.000 description 8
- 108090000862 Ion Channels Proteins 0.000 description 8
- 102000006382 Ribonucleases Human genes 0.000 description 8
- 108010083644 Ribonucleases Proteins 0.000 description 8
- 239000012491 analyte Substances 0.000 description 8
- 229940000406 drug candidate Drugs 0.000 description 8
- 230000028161 membrane depolarization Effects 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 7
- 102100029974 GTPase HRas Human genes 0.000 description 7
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000000636 Northern blotting Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 7
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002105 Southern blotting Methods 0.000 description 7
- 230000036982 action potential Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000007877 drug screening Methods 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 101150001121 KCNE1 gene Proteins 0.000 description 6
- 238000012300 Sequence Analysis Methods 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 108090000312 Calcium Channels Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102200038813 rs12720459 Human genes 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 206010047302 ventricular tachycardia Diseases 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 4
- 206010064571 Gene mutation Diseases 0.000 description 4
- 108091027305 Heteroduplex Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- -1 chemiluminescers Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 102000054766 genetic haplotypes Human genes 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 3
- 206010057926 Long QT syndrome congenital Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 206010042434 Sudden death Diseases 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000013160 medical therapy Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000001742 protein purification Methods 0.000 description 3
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 102200004228 rs179489 Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 206010042772 syncope Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000002424 x-ray crystallography Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000021548 Jervell and Lange-Nielsen syndrome Diseases 0.000 description 2
- 201000003992 Jervell-Lange Nielsen Syndrome Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 208000018452 Torsade de pointes Diseases 0.000 description 2
- 208000002363 Torsades de Pointes Diseases 0.000 description 2
- 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000007844 allele-specific PCR Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000014107 chromosome localization Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 102000046912 human KCNE1 Human genes 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012917 library technology Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 102200038776 rs12720459 Human genes 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 208000011317 telomere syndrome Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- WJMFXQBNYLYADA-UHFFFAOYSA-N 1-(3,4-dihydroxyphenyl)-6,7-dihydroxy-1,2-dihydronaphthalene-2,3-dicarboxylic acid Chemical compound C12=CC(O)=C(O)C=C2C=C(C(O)=O)C(C(=O)O)C1C1=CC=C(O)C(O)=C1 WJMFXQBNYLYADA-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000829192 Bos taurus polyomavirus 1 Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101100185881 Clostridium tetani (strain Massachusetts / E88) mutS2 gene Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102220526123 Dihydrofolate reductase_D77N_mutation Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108700035849 Drosophila Sh Proteins 0.000 description 1
- 108700031968 Drosophila eag Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000014061 Extranodal Extension Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100034154 Guanine nucleotide-binding protein G(i) subunit alpha-2 Human genes 0.000 description 1
- 101710094396 Hexon protein Proteins 0.000 description 1
- 101001070508 Homo sapiens Guanine nucleotide-binding protein G(i) subunit alpha-2 Proteins 0.000 description 1
- 101001026209 Homo sapiens Potassium voltage-gated channel subfamily A member 4 Proteins 0.000 description 1
- 101000997283 Homo sapiens Potassium voltage-gated channel subfamily C member 1 Proteins 0.000 description 1
- 101000712974 Homo sapiens Ras association domain-containing protein 7 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000016012 Phenotypic abnormality Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100037449 Potassium voltage-gated channel subfamily A member 4 Human genes 0.000 description 1
- 102100034308 Potassium voltage-gated channel subfamily C member 1 Human genes 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102000004879 Racemases and epimerases Human genes 0.000 description 1
- 108090001066 Racemases and epimerases Proteins 0.000 description 1
- 101100126906 Rattus norvegicus Kcne1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000008409 Romano-Ward Syndrome Diseases 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000013541 Shaker Superfamily of Potassium Channels Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 208000015700 familial long QT syndrome Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 101150117187 glmS gene Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000003165 hybrid screening Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000021190 leftovers Nutrition 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- 101150013854 mutS gene Proteins 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000001216 nucleic acid method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- XKCQASMZNPBLKI-UHFFFAOYSA-N phosphorosooxymethane Chemical group COP=O XKCQASMZNPBLKI-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 230000036278 prepulse Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102200004233 rs104894252 Human genes 0.000 description 1
- 102200004213 rs120074177 Human genes 0.000 description 1
- 102200004235 rs120074178 Human genes 0.000 description 1
- 102200004060 rs120074179 Human genes 0.000 description 1
- 102200038933 rs120074180 Human genes 0.000 description 1
- 102200038735 rs120074181 Human genes 0.000 description 1
- 102200038716 rs120074182 Human genes 0.000 description 1
- 102200038804 rs120074183 Human genes 0.000 description 1
- 102200038759 rs120074184 Human genes 0.000 description 1
- 102200133048 rs17857111 Human genes 0.000 description 1
- 102200038751 rs199472752 Human genes 0.000 description 1
- 102200133063 rs199473350 Human genes 0.000 description 1
- 102200133003 rs199473362 Human genes 0.000 description 1
- 102200038839 rs199473403 Human genes 0.000 description 1
- 102200038855 rs199473411 Human genes 0.000 description 1
- 102200038765 rs74462309 Human genes 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000004092 self-diagnosis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 150000003680 valines Chemical class 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Jellies, Jams, And Syrups (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9447798P | 1998-07-29 | 1998-07-29 | |
| US94477P | 1998-07-29 | ||
| US135010 | 1998-08-17 | ||
| US09/135,010 US6277978B1 (en) | 1995-12-22 | 1998-08-17 | KVLQT1—a long QT syndrome gene |
| PCT/US1999/010260 WO2000006199A1 (en) | 1998-07-29 | 1999-05-12 | Kvlqt1 - a long qt syndrome gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69936781D1 DE69936781D1 (de) | 2007-09-20 |
| DE69936781T2 true DE69936781T2 (de) | 2008-06-05 |
Family
ID=26788931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69936781T Expired - Lifetime DE69936781T2 (de) | 1998-07-29 | 1999-05-12 | Kvlqt1 - im zusammenhang mit 'long qt syndrom' |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US6277978B1 (enExample) |
| EP (1) | EP1100538B1 (enExample) |
| JP (1) | JP2002521045A (enExample) |
| AT (1) | ATE369420T1 (enExample) |
| AU (1) | AU758048B2 (enExample) |
| CA (1) | CA2336263A1 (enExample) |
| DE (1) | DE69936781T2 (enExample) |
| WO (1) | WO2000006199A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6797486B2 (en) * | 1996-09-11 | 2004-09-28 | Icagen, Incorporated | Small and intermediate conductance, calcium-activated potassium channels and uses thereof |
| US7179597B2 (en) | 2000-04-13 | 2007-02-20 | Georgetown University | Genetic diagnosis for QT prolongation related adverse drug reactions |
| US6348486B1 (en) * | 2000-10-17 | 2002-02-19 | American Home Products Corporation | Methods for modulating bladder function |
| CA2457365A1 (en) * | 2001-08-20 | 2003-02-27 | Genaissance Pharmaceuticals, Inc. | Polymorphisms associated with ion-channel disease |
| JP2006511218A (ja) * | 2002-12-21 | 2006-04-06 | ファイザー・プロダクツ・インク | 薬物誘発性不整脈に関連する方法および組成物 |
| US7537928B2 (en) * | 2003-08-22 | 2009-05-26 | Masonic Medical Research Laboratory | Mutations in ion channel proteins associated with sudden cardiac death |
| US7833718B2 (en) * | 2006-11-06 | 2010-11-16 | Masonic Medical Research Laboratory | CACNA1C nucleic acid mutations as indicators of shorter than normal QT interval and ST segment elevation associated with sudden cardiac death |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2085478A1 (en) * | 1995-12-22 | 2009-08-05 | University Of Utah Research Foundation | A long QT syndrome gene which encodes KVLQT1 and its association with minK |
| ATE211918T1 (de) | 1996-10-21 | 2002-02-15 | Morten Sloth Weidner | Pharmazeutische zusammenstellungen mit parthenium integrifolium oder mit einem extrakt oder einer komponente davon, verwendung dieses pflanzenmaterials zur herstellung von medizin und ein verfahren zur extraktherstellung von parthenium integrifolium |
| DK1066042T3 (da) | 1998-03-26 | 2006-12-18 | Phytopharm Plc | Steroidale saponiner til behandling af Alzheimers sygdom |
| AUPP797598A0 (en) | 1998-12-30 | 1999-01-28 | Butters, Desley | Therapeutic agent |
| US6194469B1 (en) | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
| US20010006686A1 (en) | 1999-03-19 | 2001-07-05 | David G. Corley | Inflammatory mediation obtained from atractylodes lancea |
-
1998
- 1998-08-17 US US09/135,010 patent/US6277978B1/en not_active Expired - Lifetime
-
1999
- 1999-05-12 DE DE69936781T patent/DE69936781T2/de not_active Expired - Lifetime
- 1999-05-12 EP EP99922910A patent/EP1100538B1/en not_active Expired - Lifetime
- 1999-05-12 AT AT99922910T patent/ATE369420T1/de not_active IP Right Cessation
- 1999-05-12 JP JP2000562052A patent/JP2002521045A/ja active Pending
- 1999-05-12 CA CA002336263A patent/CA2336263A1/en not_active Abandoned
- 1999-05-12 AU AU39800/99A patent/AU758048B2/en not_active Ceased
- 1999-05-12 WO PCT/US1999/010260 patent/WO2000006199A1/en not_active Ceased
-
2000
- 2000-06-19 US US09/597,735 patent/US6420124B1/en not_active Expired - Lifetime
- 2000-06-19 US US09/597,732 patent/US6451534B1/en not_active Expired - Lifetime
- 2000-06-19 US US09/597,731 patent/US6582913B1/en not_active Expired - Lifetime
-
2003
- 2003-02-20 US US10/368,643 patent/US6972176B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20030170708A1 (en) | 2003-09-11 |
| US6451534B1 (en) | 2002-09-17 |
| AU3980099A (en) | 2000-02-21 |
| WO2000006199A8 (en) | 2001-04-12 |
| US6972176B2 (en) | 2005-12-06 |
| DE69936781D1 (de) | 2007-09-20 |
| US6582913B1 (en) | 2003-06-24 |
| AU758048B2 (en) | 2003-03-13 |
| CA2336263A1 (en) | 2000-02-10 |
| ATE369420T1 (de) | 2007-08-15 |
| EP1100538B1 (en) | 2007-08-08 |
| JP2002521045A (ja) | 2002-07-16 |
| US6277978B1 (en) | 2001-08-21 |
| EP1100538A2 (en) | 2001-05-23 |
| EP1100538A4 (en) | 2003-07-02 |
| US6420124B1 (en) | 2002-07-16 |
| WO2000006199A1 (en) | 2000-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69837565T2 (de) | Mutationen des menschlichen mink gens, die mit arrhytmie verbunden sind | |
| US7297489B2 (en) | Mutations in and genomic structure of HERG—a long QT syndrome gene | |
| DE69636870T2 (de) | KVLQT1 - EIN GEN DES LONG-QT-SYNDROMS, WELCHES FÜR KVLQT1 KODIERT UND WELCHES SICH MIT Mink ZUSAMMENSETZT, UM Iks-KALIUMKANÄLE DES HERZENS ZU BILDEN | |
| WO1997023598A9 (en) | A long qt syndrome gene which encodes kvlqt1 and its association with mink | |
| DE69635751T2 (de) | "long qt" gene und methode zur diagnose oder prävention des "long qt" syndroms | |
| DE69936781T2 (de) | Kvlqt1 - im zusammenhang mit 'long qt syndrom' |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| R082 | Change of representative |
Ref document number: 1100538 Country of ref document: EP Representative=s name: DF-MP, DE |